다른 뉴스레터 둘러보기
FDA 자료 Product-Specific Guidances for Generic Drug Development | FDA updates on valsartan recalls [클릭] Impact Story: Evaluating the Potential of Microengineered Human Cellular Systems to Predict Drug Effects in the Clinic [클릭]
'박사급 인력' 모시기 분주한 바이오벤처들 | GC녹십자, 만성 B형 간염 완치 앞장 | 사노피, 6번째 면역관문억제제 '리브타요' FDA 허가
FDA 자료 Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use Guidance for Industry | Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry (PDF - 195KB)
매출 수십배 거뜬'...바이오기업에 쏠린 자금의 기대감 | 가격은 비싸고 제품은 많고…제네릭 제도 개선안에 관심↑ | 삼성, 20조 휴미라 바이오시밀러 미국 허가 신청
FDA 자료 Good Review Management Principles and Practices for New Drug Applications and Biologics License Applications | ANDA Submissions — Content and Format of Abbreviated New Drug Applications |